  Polygenic risk scores (PRS) summarize the combined effect of common risk
variants and are associated with breast cancer risk in patients without
identifiable monogenic risk factors. One of the most well-validated PRSs in
breast cancer to date is PRS313, which was developed from a Northern European
biobank but has shown attenuated performance in non-European ancestries. We
further investigate the generalizability of the PRS313 for American women of
European (EA), African (AFR), Asian (EAA), and Latinx (HL) ancestry within one
institution with a singular EHR system, genotyping platform, and quality
control process. We found that the PRS313 achieved overlapping Areas under the
ROC Curve (AUCs) in females of Lantix (AUC, 0.68; 95 CI, 0.65-0.71) and
European ancestry (AUC, 0.70; 95 CI, 0.69-0.71) but lower AUCs for the AFR and
EAA populations (AFR: AUC, 0.61; 95 CI, 0.56-0.65; EAA: AUC, 0.64; 95 CI,
0.60-0.680). While PRS313 is associated with Hormone Positive (HR+) disease in
European Americans (OR, 1.42; 95 CI, 1.16-1.64), for Latinx females, it may be
instead associated with Human Epidermal Growth Factor Receptor 2 (HER2+)
disease (OR, 2.52; 95 CI, 1.35-4.70) although due to small numbers, additional
studies are needed. In summary, we found that PRS313 was significantly
associated with breast cancer but with attenuated accuracy in women of African
and Asian descent within a singular health system in Los Angeles. Our work
further highlights the need for additional validation in diverse cohorts prior
to clinical implementation of polygenic risk scores.
